Leaflet ATRYN 1750UI 1750IU powder for intravenous injection solution


Indicated for: antithrombin deficiency

Substance: antithrombin alfa (coagulation factor)

ATC: B01AB02 (Blood and blood forming organs | Antithrombotic agents | Heparin group)

Antithrombin alfa is a recombinant form of antithrombin, a natural protein that plays a crucial role in regulating blood coagulation. It is used in the treatment and prevention of thrombotic complications in patients with congenital antithrombin deficiency or in other clinical situations requiring supplementation of this protein.

Antithrombin alfa works by inhibiting enzymes in the coagulation cascade, including thrombin and factors Xa and IXa, thereby preventing excessive blood clot formation. It is administered intravenously, usually before surgical procedures or in emergency situations.

Side effects are rare but may include allergic reactions, fever, or thrombocytopenia. Administration must be performed under strict medical supervision, with careful monitoring of coagulation parameters.

Antithrombin alfa is an innovative medication that helps prevent and treat thrombotic complications, offering a safe and effective alternative for patients with antithrombin deficiency.

General data about ATRYN 1750UI 1750IU

  • Substance: antithrombin alfa
  • Date of last drug list: 01-07-2013
  • Commercial code: W51430001
  • Concentration: 1750IU
  • Pharmaceutical form: powder for intravenous injection solution
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.